Logo

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

Share this
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

Shots:

  • The approval is based on the P-III KEYNOTE-564 trial evaluating Keytruda (200mg, IV, q3w for 1yrs.) vs PBO in a ratio (1:1) in 994 patients with intermediate-high or high risk of recurrence of RCC or M1 NED, following nephrectomy and resection of metastatic lesions
  • The results showed an improvement in DFS, 32% reduction in the risk of disease recurrence or death & the median duration of exposure was 11.1mos.
  • Merck has a broad clinical development program exploring Keytruda, as monothx. or in combination, as well as other investigational products across multiple settings and stages of RCC, including adjuvant and advanced or metastatic disease

Ref: Merck | Image: Merck

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions